XPRO Expro Ltd
$17.58▲ +0.06%
Energy
Other
After hours
$17.58▲ +0.09%
Sep 11, 4:01 PM ET
Volume 487.0K
Avg Volume (10D) 821.1K
Key Metrics & Fundamentals
Market Cap
$1.98B
P/E Ratio
97.7
Div Yield
–%
52W Range
11.60 - 19.23
% vs 50 MA
4.23%
% vs 200 MA
9.35%
RSI-14
49.3
MACD Histogram
-0.1300
Beta (1Y vs SPY)
1.06
Free Cash Flow
$50.28M
Gross Rev
$393.18M
Gross Profit
$36.23M
EBITDA
$64.89M
COGS
$356.95M
Operating Exp
$19.66M
Operating Income
$16.58M
EBIT
$16.58M
Pretax Income
$10.18M
Net Income
$2.03M
EPS (Diluted)
0.02
Price & Volume History
Loading chart…
Recent News
3 Energy Stocks We’re Skeptical Of
StockStory · Aug 28, 2026 2:24 PM
3 Reasons to Sell XPRO and 1 Stock to Buy Instead
StockStory · Aug 10, 2026 7:57 PM
1 Russell 2000 Stock with Solid Fundamentals and 2 We Brush Off
StockStory · Aug 3, 2026 11:17 PM
How Expro’s Higher 2026 Guidance and Buyback Will Impact Expro (XPRO) Investors
Simply Wall St. · Aug 2, 2026 2:08 AM
Expro (XPRO) Could Be 11% Undervalued As 2026 Revenue Guidance Rises
Simply Wall St. · Aug 1, 2026 11:10 PM
Expro (XPRO) Stock Trades Up, Here Is Why
StockStory · Jul 29, 2026 3:25 AM
Expro Group Q2 Earnings Call Highlights
MarketBeat · Jul 28, 2026 9:04 PM
Sector Update: Energy Stocks Decline Tuesday Afternoon
MT Newswires · Jul 28, 2026 5:51 PM
Sector Update: Energy Stocks Edge Higher Pre-Bell Tuesday
MT Newswires · Jul 28, 2026 1:24 PM
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday Amid Renewed Pressure on Semiconductor Stocks
MT Newswires · Jul 28, 2026 1:00 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See XPRO's money flow as a full page
Social Sentiment
Avg +0.65 · 2 posts
DDNewsSay less — here’s the full 3AM, typo-ridden, cracked-out WSB rant version of (mystery stock that involves an I and a N and a M and a B:
r/wallstreetbets · Aug 23, 2025
The poster views 'Xpro™' positively, believing it offers solutions to various medical conditions.
very_positive
+0.90
NewsDiscussionDD[INMB] INmune Bio Inc. - High risk/high reward
r/investing · Jun 2, 2025
The post discusses XPro as a novel approach to treating AD and positive clinical trial results.
positive
+0.40
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.